Evaluation of a New Clinical Tool to Enhance Clinical Care of Control-IQ Users.

Background: The purpose of this study was to develop and test a new Clinic Tool to assist health care professionals with clinical care of persons with diabetes using the Control-IQ system.
Methods: A Clinic Tool was iteratively developed with input from diabetes clinicians, which outlined a systematic process for assessing data, reviewing insulin settings, providing education, and documenting the encounter. Diabetes clinicians were recruited to trial the Clinical Tool in up to five clinical encounters (in-person, telehealth, or telephone). Quantitative surveys and free-text responses, including a knowledge quiz and the System Usability Scale (SUS), were administered to determine clinician satisfaction, confidence, knowledge, and implications for practice.
Results: Twenty-nine clinicians (43% endocrinologists, mean 10.7 years in practice) enrolled in the study and completed 89 encounters using the Control-IQ Clinic Tool. Participants spent an average of 10 minutes using the Tool and reported excellent SUS scores within the 90%-95% percentile for usability. Knowledge quiz scores increased in 42% of participants. Both familiarity with Control-IQ and confidence providing clinical care to Control-IQ users significantly improved ( P = .009 and P < .001 respectively). Ninety percent of participants agreed that the Tool will change their clinical care going forward.
Conclusion: The Control-IQ Clinical Tool is highly usable and impacted clinical care delivery to Control-IQ users. Tools that serve to improve clinician confidence in delivery of care to diabetes device users should be expanded, leveraged, and studied to assess the impact on adherence and glycemic control for persons with diabetes.
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LHM has received speaking/consulting honoraria from Tandem Diabetes, Dexcom, and Capillary Biomedical and is a certified trainer for Medtronic Minimed. GPF has received speaking consulting honoraria from Tandem Diabetes, Dexcom, Medtronic, Insulet, Abbott, Lilly, and Beta Bionics. The institution receives research/project grants from Medtronic, Tandem Diabetes, Insulet, Dexcom, Abbott, Lilly, and Beta Bionics. CB, SC, and BM have nothing to disclose.